Arterial Occlusive Events in a Patient With Chronic Myeloid Leukemia Treated With Ponatinib Authors: Osamu Imataki, Makiko Uemura Published: 2024 ABSTRACT ABSTRACTArterial occlusive events (AOE) are rare adverse event in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor such as ponatinib. We treated a 47‐year‐old woman with chronic myeloid leukemia. She was failed to achieve optimal molecular response in prior two lines tyrosine kinase inhibitors treatment (dasatinib and bosutinib) for first 30 months. Finally, she was treated with ponatinib and achieve complete molecular remission in 28 months. However, she was suffered from AOE, in bilateral stenosis of the middle cerebral arteries. The patient's responsible vascular lesions of AOE were atypical site rather than usually affected lesions in common arteriosclerosis.Keywords: arterial occlusive events, cerebral vascular disease, chronic myeloid leukemia, ponatinib, tyrosine kinase inhibitor Summary Arterial occlusive events (AOE) are specific adverse events observed in patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors. Arterial occlusive events (AOE) are specific adverse events observed in patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors. We present the case of a 47‐year‐old female patient with CML who was treated with ponatinib and manifested AOEs in the bilateral middle cerebral arteries, which occurred atypically. We present the case of a 47‐year‐old female patient with CML who was treated with ponatinib and manifested AOEs in the bilateral middle cerebral arteries, which occurred atypically. Introduction Arterial occlusive events (AOE) in patients with chronic myeloid leukemia (CML) treated with ponatinib are well‐known adverse events among hematologists. The risk for AOE by tyrosine kinase inhibitors (TKIs) is antecedent cardiovascular diseases [1]. We present a 47‐year‐old female patient with CML treated with TKIs (dasatinib, bosutinib, and ponatinib) for 5 years. The patient demonstrated a partial cytogenetic response to dasatinib up to 140 mg/day during the first 15 months, molecular response [MR] of 3.0. She subsequently received bosutinib of up to 400 mg/day for the next 15 months, which kept her disease stable (MR3.0) and intolerable due to hepatic damage. We finally switched TKI to ponatinib for 28 months, yielded molecular response with MR5.0. However, the patient complained of headache, her contrast‐enhanced computed tomography and magnetic resonance imaging showed bilateral stenosis of the middle cerebral arteries (MCA) (Figure 1A). The neurosurgeons decided to perform a selective operation on the left side of the MCA. The patient's cerebral MRI showed an intact cortex without any acute infarction signs, and the SPECT scan indicated no decreased perfusion in the cerebrum. The patient initially underwent anti‐coagulant therapy with continuous heparin infusion (20,000 IU/day), until receiving bypass operation. She underwent bypass surgery connecting the left MCA with the superficial temporal artery (Figure 1B). The bypass operation improved the patient's symptoms, including headache associated with hypertension. The responsible vascular lesions in this case were bilaterally symmetrical MCAs, which is unusually affected in common arteriosclerosis. The patient's angiography. (A) The patient's angiography showed bilateral stenosis of the middle cerebral arteries (MCA) at the onset (red arrows). (B) After the operation, blood flow of the left MCA was regained with the superficial temporal artery (red arrow). Author Contributions Osamu Imataki: conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, validation, writing – original draft. Makiko Uemura: conceptualization, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing – review and editing. Ethics Statement We obtained approval from the Kagawa University Hospital Institutional Review Board (H23‐023). This study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The subjects have provided written informed consent to publish their case (including publication of images). Consent Written informed consent was obtained from the patient for publication of this study. Conflicts of Interest The authors declare no conflicts of interest. Funding: The internal funding from JSPS KAKENHI supported this work (Grant Numbers JP23K11850). We have no other financial relationships to disclose. Data Availability Statement All data generated or analyzed during this study have been included in this published article. Data is available on request because of privacy/ethical restrictions. Reference Associated Data Data Availability Statement All data generated or analyzed during this study have been included in this published article. Data is available on request because of privacy/ethical restrictions.